These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669 [TBL] [Abstract][Full Text] [Related]
3. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172 [TBL] [Abstract][Full Text] [Related]
4. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials. Tian Q; Gao H; Zhou Y; Yang J Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224 [TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis. Behrouzi R; Armstrong AC; Howell SJ Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881 [TBL] [Abstract][Full Text] [Related]
6. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271 [TBL] [Abstract][Full Text] [Related]
7. Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer. Zhao Q; Jiang M; Liu J; Zhang M; He M; Zhou S; Wang J; Mo H; Lan B; Yuan P; Zhang P; Ma F; Li Q; Xu B Cancer Biol Med; 2024 Sep; 21(10):934-50. PubMed ID: 39267478 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934 [TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials. Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560 [TBL] [Abstract][Full Text] [Related]
10. Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis. Xia LY; Cao XC; Hu QL; Xu WY Front Oncol; 2024; 14():1413674. PubMed ID: 39267829 [TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients. Kubeczko M; Gabryś D; Krzywon A; Jarząb M Br J Radiol; 2024 Oct; 97(1162):1627-1635. PubMed ID: 39120877 [TBL] [Abstract][Full Text] [Related]
12. Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis. Ralser DJ; Kiver V; Solomayer EF; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Müller C; Rambow AC Arch Gynecol Obstet; 2024 Oct; ():. PubMed ID: 39373732 [TBL] [Abstract][Full Text] [Related]
13. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386 [TBL] [Abstract][Full Text] [Related]
15. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454 [TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300 [TBL] [Abstract][Full Text] [Related]
17. Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer. Lobo-Martins S; Corredeira P; Cavaco A; Rodrigues C; Piairo P; Lopes C; Fraga J; Silva M; Alves P; Wachholz Szeneszi L; Barradas A; Castro Duran C; Antunes M; Nogueira-Costa G; Sousa R; Pinto C; Ribeiro L; Abreu C; Torres S; Quintela A; Mata G; Megías D; Ribot J; Serre K; Casimiro S; Silva-Santos B; Diéguez L; Costa L Cells; 2024 Aug; 13(16):. PubMed ID: 39195280 [TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. Brandão M; Maurer C; Ziegelmann PK; Pondé NF; Ferreira A; Martel S; Piccart M; de Azambuja E; Debiasi M; Lambertini M ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847835 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251 [TBL] [Abstract][Full Text] [Related]
20. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy. Akdag G; Dogan A; Yildirim S; Kinikoglu O; Mokresh ME; Alomari O; Turkoglu E; Isik D; Sürmeli H; Basoglu T; Sever ON; Odabas H; Yildirim ME; Turan N Cureus; 2024 Jun; 16(6):e63362. PubMed ID: 39070363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]